Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Mutabilis logo — New Antibiotics against Multi Resistant Gram-negative bacter...

Mutabilis

New Antibiotics against Multi Resistant Gram-negative bacterial infections

Founded 2001 France France 21 employees Grant Total: $13.40M Biotechnology

General Information

Company Name Mutabilis
Founded Year 2001
Location France France
Employees 21
Industries Biotechnology
Funding Stage Grant
Social

BounceWatch is an independent company data service, not affiliated with Mutabilis. To contact Mutabilis, visit mutabilis.fr.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Mutabilis compare?

A PDF of Mutabilis and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Mutabilis soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Mutabilis

Mutabilis is a French biopharmaceutical company focusing on the development of novel non-beta-lactam PBP-targeting antibacterial drugs called dabocins. These drugs aim to combat the most challenging Gram-negative bacterial infections. Derived from the non-natural diazabicyclooctane scaffold, dabocins exhibit remarkable stability to beta-lactamase hydrolysis. The company's expertise in the derivatization and characterization of this scaffold is a distinguishing factor. Notably, Mutabilis' pipeline includes EBL-1463, an intravenous antibiotic targeting carbapenem-resistant Enterobacterales, supported by ENABLE (ND4BB/IMI), and 2G-DAB, a second-generation dabocin program backed by the Repair Impact Fund aiming to broaden the coverage to both Enterobacterales and non-fermenters. Furthermore, Mutabilis received a $6.40M grant investment on 01 September 2020 from CARB-X. For more information, visit their website at mutabilis.fr. Overall, Mutabilis showcases promising innovation in the biotechnology sector, particularly in addressing antibiotic resistance.

Taxonomy: Biopharmaceutical, Antibiotics, Gram-negative bacterial infections, Dabocins, Non-beta-lactam PBP-targeting, Carbapenem-resistant Enterobacterales, Drug development, Bacterial resistance, Research and development, Infectious diseases, Diazaibicyclooctane scaffold, Medical innovation, French biotech industry, Investment potential

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Grant $6.40M 1
CARB-X
CARB-X
01 Sep 2020
Venture Round €7.00M 1
Repair Impact Fund
Repair Impact Fund
06 Jan 2020
Venture Round Undisclosed 1
Omnes Capital
Omnes Capital
01 Jan 2004

Mutabilis Alternatives & Competitors

View All Alternatives
Mutabilis vs
Zikani Therapeutics
Zikani Therapeutics

A new era in antibiotic treatment targeting resilient gram-negative bacteria, delivering advanced or...

Series A
Biotechnology, Life Sciences
Mutabilis vs
Synereca Pharmaceuticals
Synereca Pharmaceuticals

Pioneering orally active drugs to rejuvenate antibiotic efficacy against lung, urinary tract, and sk...

Venture round
Biotechnology, Health Care
Mutabilis vs
Curza
Curza

Small molecule therapeutics R&D company focused on developing new drugs to combat antibiotic resista...

Venture round
17 employees
Biotechnology, Health Care
View all alternatives

FAQ About Mutabilis

New Antibiotics against Multi Resistant Gram-negative bacterial infections
Mutabilis was founded in 2001.
Mutabilis is headquartered in France.
Mutabilis operates in Biotechnology. Its work centres on Biopharmaceutical, Antibiotics, Gram-negative bacterial infections and Dabocins.
Mutabilis has approximately 21 employees.
Mutabilis has completed 3 funding rounds, raising a total of $13.40M. The latest funding stage is Grant.
Top alternatives and competitors to Mutabilis include Zikani Therapeutics, Synereca Pharmaceuticals, Curza, Prokaryotics, Inc., SaNOtize Research and Development Corp.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Mutabilis and Zikani Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Mutabilis, https://bouncewatch.com/company/mutabilis, updated 9 November 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes